PwC
About this report
As part of its Improving America’s Health series, PwC has periodically surveyed industry executives on their relationship with the FDA.
In summer 2014, PwC’s Health Research Institute and Biocom polled 100 senior executives on issues such as regulations, the development of new therapies, and patient engagement.
1000 adult consumers were also surveyed about their views of the FDA, the pharmaceutical/life sciences industry and consumer access to therapies.
Slide 2
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Key findings
Slide 3
Executives say that the FDA has become a more communicative and open partner
Executives understand that balancing innovation and risk comes with tradeoffs
Industry attitudes are shifting when it comes to determinations of value
Consumers want more engagement from both the FDA and industry4
1
2
3
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
An evolving regulatory process
Slide 5
Source: 2014 HRI Pharmaceutical and Life Sciences Executive Survey
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
The FDA’s budget relies heavily on industry fees
Slide 6
Source: 2014 HRI Pharmaceutical and Life Sciences Executive Survey
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
The FDA’s standard review times have decreased
Slide 7
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Priority reviews have also improved
Slide 8
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
The FDA has become a better communicator…
Steps taken by the FDA to improve working relationships with companies
Slide 9
Source: 2014 HRI Pharmaceutical and Life
Sciences Executive Survey
Better quality and more frequent communications with the FDA helps executives anticipate the agency’s expectations and satisfy regulatory requirements
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
But executives still question the value of user fees
Areas that executives believe have improved the most as a result of increased PDUFA/MDUFA fees
Slide 10
Just 32% thought the fees they paid have resulted in shorter review times and only 34% think the fees help accelerate innovation
Source: 2014 HRI Pharmaceutical and Life
Sciences Executive SurveyThe FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Industry wants the FDA to prioritize innovation
Areas that executives believe have improved the most as a result of increased PDUFA/MDUFA fees
Slide 11
Only 34% of executives think user fees help accelerate innovation
Source: 2014 HRI Pharmaceutical and Life
Sciences Executive Survey
User fees accelerate innovation
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Experts say…
Slide 12
“Science is advancing so quickly, it’s difficult for any single organization to stay on top of everything. We need a system in the 21st
century that allows regulators to access the scientific expertise they need, both internally and externally, in a timely manner.”
- Stacy Holdsworth, senior advisor of US regulatory policy and strategy at Eli Lilly & Company
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Experts say…
Slide 13
- Andrew von Eschenbach, former FDA commissioner
“You have to recognize that the user fee program is only addressing the review cycle and that’s not the issue. Review is only one piece. You need a much broader view. The issue is the process from the very beginning of development to the post market. And the FDA influences that entire process.”
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Experts say…
Slide 14
- Fred Hassan, former CEO of Schering-Plough who now serves as a managing director at Warburg Pincus
“The FDA needs to be part of the innovation engine. I don’t think they currently see that as a primary role”
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Changes are already being implemented
Slide 15
Executives are less familiar with new programs
Familiarity with accelerated approval programs
The FDA and industry: A recipe for collaborating in the New Health Economy
Source: 2014 HRI Pharmaceutical and Life
Sciences Executive Survey
PwC
Case study: Breakthrough therapies
Slide 17
“I’m talking to the FDA every week about IMBRUVICA. My experience with the FDA, as part of that process, has been overwhelmingly positive. That doesn’t mean issues never arise, but I’m happy because my expectation of the FDA is that we can work through those issues and get them resolved, before they become larger issues.”
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Case study: Breakthrough therapies
Slide 18
“I’m talking to the FDA every week about IMBRUVICA. My experience with the FDA, as part of that process, has been overwhelmingly positive. That doesn’t mean issues never arise, but I’m happy because my expectation of the FDA is that we can work through those issues and get them resolved, before they become larger issues.”
- Urte Gayko, senior vice president of global regulatory affairs at Pharmacyclics on her experience managing Imbruvica, a breakthrough therapy drug
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Case study: Breakthrough therapies
Slide 19
“It does seem to be changing the way the agency is doing things. If this is a promising direction, we need to ask what else needs to change along with it. The breakthrough process is focused on drug review and approval but there are other things that need to get done at the same time such as review of good manufacturing processes.”
- Mark McClellan, former FDA commissioner and current senior fellow and director of the Health Care Innovation and Value Initiative at the Brookings Institution
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Consumers are willing to take on more risk
Slide 21
Respondents overwhelmingly agreed that patients with life-threatening conditions should be able to access experimental therapies.
The FDA and industry: A recipe for collaborating in the New Health Economy
Source: 2014 HRI Pharmaceutical and Life
Sciences Consumer Survey
PwC
Executives support consumers’ desire for access
Slide 22
77% of executives agree that consumers willing to assume grater risks should have access to experimentaltherapies.
The FDA and industry: A recipe for collaborating in the New Health Economy
Source: 2014 HRI Pharmaceutical and Life
Sciences Executive Survey
PwC
But speedier access may require new thinking
Slide 23
“We’re looking at outcomes data and how it should influence regulatory decisions.”
“Quickness to market is clearly a basic principle. With that comes an even greater need for post-market surveillance.”
- Stacy Holdsworth, senior advisor of US regulatory policy and strategy at Eli Lilly & Company
- Ray Woosley, president emeritus of the Critical Path Institute and founder of CredibleMeds – an organization focused on safe medication use.
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Experts say…
Slide 25
“We don’t want to squelch innovation, but tell me what I'm getting for my healthcare costs. Show me that these new technologies are superior.”
- Scott Josephs, national medical officer at Cigna Corp. at an Advanced Medical Technology Association meeting on October 2014
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Executives attitudes are shifting on value
Slide 26
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Global experiences may shape industry views on value
Slide 27
HRI’s survey suggests harmonization of regulatory requirements would make it easier, and faster, to bring a new drug to market worldwide.
Source: 2014 HRI Pharmaceutical and Life Sciences Executive Survey
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Cost is not considered
at all
Only if a patient
asks
To a lesser degree
To some degree
To a significant
degree
Cost is a top consideration for prescribers
This matters to consumers, who rank a physician’s recommendation as the most important factor that influences their treatment decisions, followed by their own out-of-pocket costs.
1% 2% 5% 38% 54%
Is cost a factor when deciding whether or not to prescribe a drug?
The FDA and industry: A recipe for collaborating in the New Health Economy Source: 2014 HRI Clinician Survey
Slide 28
PwC
Cost-conscious consumers also seek value
Slide 29
% of Americans deciding not to purchase medical services due to cost
Willingness to pay more for a personalized medical product
The FDA and industry: A recipe for collaborating in the New Health Economy
Source: 2014 HRI Pharmaceutical and Life
Sciences Consumer Survey
PwC
Experts say…
Slide 31
“Today’s consumers make decisions in conjunction with medical authority, not because of a medical authority.”
- Ido Hadari, CEO of Treato, in an interview with HRI
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Experts say…
Slide 32
“Having a seat at the table is important, but how do you make sure the patient perspective can be turned into data points that can inform and influence the review process? We’re talking about quickly moving from a lofty goal of making patients part of the system to a very technical conversation about how to make it happen.”
- Cecilia Arradaza, Executive Director of the Milken Institute, which includes FasterCures -an organization focused on speeding medical innovation
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Experts say…
Slide 33
“I’ve told industry that patients can contribute to the conversation. That the patient voice is important earlier in the process, such as how clinical trials are designed.”
- Diane Dorman, vice president of public policy for the National Organization for Rare Disorders
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Experts say…
Slide 34
“No patient community has ever done this and it sets the stage for new partnerships with the FDA.”
- Pat Furlong, founding president and CEO of Parent Project Muscular Dystrophy, explained how her group created the first patient centered guidance document on clinical trial design.
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Case Study: Priority review vouchers
Innovative methods to promote research in rare diseases
Slide 35
PwC
“The question isn’t how to get a drug approved. The question is how you get a private company to make the drug in the first place.”
Case study: Priority review vouchers
Slide 36
- Nancy Goodman, founder and executive director of Kids V Cancer, a patient organization that promotes pediatric cancer research.
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Future considerations
Slide 38
Prioritize consumer input
Demonstrate value to regulators and purchasers
Seek new alliances
Pursue new opportunities to minimize risk and accelerate access
Enrich the dialogue
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Future considerations
Slide 39
Prioritize consumer input
Companies should seek out consumers’ views, diligently incorporate their input at every stage and share this information with the FDA.
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Future considerations
Slide 40
Demonstrate value to regulators and purchasers
Manufacturers will need to demonstrate value over existing therapies as both purchasers and consumers look for products that meet their needs.
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Future considerations
Slide 41
Seek new alliances
A greater reliance on public-private partnerships could provide a forum for the exchange of ideas. For instance, the Medical Device Innovation Consortium coordinates efforts of industry and regulators to develop new tools, methods and technologies.
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Future considerations
Slide 42
Pursue new opportunities to minimize risk and accelerate access
Pharmaceutical and life sciences companies should partner with the FDA to facilitate early access to experimental drugs for eligible patients with articulated risks. Continued investment in new tools and technology, such as biomarkers, may help manufacturers and regulators assess risk more accurately and quickly.
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Future considerations
Slide 43
Enrich the dialogue
Communicate more often and effectively with the FDA. Doing so will allow companies to build stronger relationships with agency officials, including the reviewers tracking their products. These interactions can help companies understand the agency’s thinking and compile stronger applications to avoid multiple review rounds.
The FDA and industry: A recipe for collaborating in the New Health Economy
PwC
Contacts
Slide 45
The FDA and industry: A recipe for collaborating in the New Health Economy
Michael MentesanaPrincipal, Pharmaceutical and Life Sciences(646) [email protected]
Chandresh HarjivanPrincipal, Pharmaceutical and Life Sciences(202) [email protected]
Bobby ClarkSenior Manager, Health Research Institute(202) [email protected]
Thank you
2015 PricewaterhouseCoopers LLP. All rights reserved. PwC refers to the United States
member firm, and may sometimes refer to the PwC network. Each member firm is a separate
legal entity. Please see www.pwc.com/structure for further details.
To download a full copy of The FDA and Industry: A recipe for collaborating in the New Health Economy, please visit our site:
http://www.pwc.com/us/hripharmalifesciencesfda